1. Skip to navigation
  2. Skip to content
  3. Skip to sidebar


  • Roger L. Whiting, Ph.D.

    Co-founder, President and CEO

    Roger Whiting brings substantial scientific and management expertise to Altos Therapeutics. Dr. Whiting was previously responsible for the creation of ROXRO Pharma, along with his co-founder, Dr. Roberto Rosenkranz. ROXRO Pharma in-licensed, developed, and obtained marketing approval for SPRIX® (ketorolac tromethamine nasal spray) utilizing a semi-virtual business model. Luitpold Pharmaceuticals, a US subsidiary of Daiichi Sankyo, acquired ROXRO in December 2010. Prior to his role as President and Chief Scientific Officer at ROXRO, Dr. Whiting was the

    Senior Vice President and Head of the Neurobiology Business Unit of Roche Bioscience, a unique industry concept for developing drugs. Prior to the acquisition by Roche he was Syntex’s Senior Vice President and Head of Basic Research, North America. Dr. Whiting began his pharmaceutical career at Beecham Research Laboratories (UK) following a period as a Lecturer at the University of Aston. Dr. Whiting received his B. Pharm. (Spec. Hons.) from Bradford University and his Ph. D. from the University of Aston under the tutorship of Dr. M.D. Day. Dr. Whiting serves on the Board of Directors of VM Pharma and Leuchemix and as a scientific advisor to Alavita, NovaBay and VM Discovery. He is an author on over 100 original papers, reviews, and patents.

    show more
  • Roberto Rosenkranz Ph.D. MBA.

    Co-founder, Executive Chairman

    Co-founder, and Executive Chairman Dr. Roberto Rosenkranz, Ph.D., MBA, brings both a scientific and business background to Altos Therapeutics, with thirty years of pharmaceutical experience in key positions at Syntex, Roche, Scios and Roxro Pharma Inc. Most recently he was Co-founder, Chairman, and Chief Executive Officer of Roxro Pharma Inc. where he along with co-founder Dr. Roger Whiting successfully in-licensed, developed and obtained market approval for Sprix® (ketorolac tromethamine) for the management of moderate to moderately severe pain. In December 2010, Luitpold Pharmaceuticals,

    a US subsidiary of Daiichi Sankyo, acquired Roxro Pharma Inc. Prior to that; he was Chief Operating Officer of Scios Inc., a public biopharmaceutical company. Dr Rosenkranz was also a business unit director at Roche Laboratories and has held several director positions at Syntex in managed care sales, business development, marketing research, and new product planning. Dr. Rosenkranz served on the boards of Gemini Holdings PLC, a U.K. genomics company, CombiMatrix Corporation, a Seattle biotechnology company, and currently serves on the board of FibroGen, Inc. of San Francisco, California, Pherin Pharmaceuticals of Menlo Park, California and the Williams Foundation. Dr. Rosenkranz is a graduate of Stanford University and earned his Ph.D. at the University of California, Davis and has published over 70 scientific papers and abstracts and holds six patents. Dr. Rosenkranz also has a Master’s in Business Administration from Santa Clara University.

    show more
  • Julian Stern

    Co-founder, Secretary

    Julian Stern is of counsel in Goodwin Procter’s Business Department and a member of the Technology Companies Group. He focuses his practice on technology and health-related companies. Mr. Stern has extensive experience with the licensing of domestic and foreign patents and other proprietary rights by and to technology companies, as well as the exploitation of their technology through joint ventures, corporate partnering, research and development and distribution agreements. He has also been involved in a number of creative financing arrangements for technology clients. Prior to joining

    Goodwin Procter, Mr. Stern was a shareholder in the Silicon Valley office of Heller Ehrman, where he was a past chair and served on its executive committee for more than 20 years. Mr. Stern was the incorporator of ALZA Corporation and has served as its Secretary and a director since its founding until its merger with Johnson and Johnson. He was the incorporator of Affymax and served as its Secretary and a managing director from inception until its acquisition by Glaxo. Mr. Stern was also the incorporator of Cetus Corporation and served as its Secretary since incorporation and as a director until its acquisition by Chiron and has been an advisory director of Chiron. He is the incorporator of A.P. Pharma, Inc.  Maxygen, Inc. Roxro Pharma Inc and Altos Therapeutics LLC and has served as their Secretary since their incorporation, as well as being Secretary and a Director of a number of privately held technology companies.

    show more

Have questions?

Contact us with questions or comments.

Contact us now